Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash

Legend Biotech's Carvykti, a CAR T-cell therapy for multiple myeloma, is explored with Alan Bash, President of Carvykti at Legend Biotech. Bash recounts his career shift from journalism to the mission-driven pharmaceutical industry, highlighting his work on checkpoint inhibitors at BMS. The conversation emphasizes the pivotal partnership with J&J that enabled Carvykti's commercial success, marked by $555 million in sales for Q4 2025 and 10,000 patients treated. Bash underscores the importance of educating physicians and patients about the benefits of CAR T therapy as a second-line treatment, detailing the company's efforts to expand market reach through targeted education and awareness campaigns. Looking ahead, Legend Biotech is preparing for competition and focusing on pipeline development, including in vivo CAR T-cell therapy.